BioFactura announces initiation of Phase I study of BFI-751, a Stelara® (ustekinumab) biosimilar
Share Article
BioFactura, a leading developer of high-value biosimilar and biodefense drugs using its patented StableFastTM platform, announces today the initiation of a pivotal PK (pharmacokinetics) Phase 1 Clinical Trial for its Ustekinumab Biosimilar (BFI-751), to assess the effects on healthy human volunteers compared to the biologic medicine, Stelera®.
BioFactura Given the prevalence and impact of autoimmune diseases on people across the globe, it is exciting to be taking the next step forward to making a positive impact on these patients’ lives. - Dr. Jeffrey Hausfeld, Chairman of the Board and Chief Medical Officer of BioFactura, Inc.
BioFactura Announces Initiation of Phase I Study of BFI-751, a Stelara® (ustekinumab) Biosimilar ibtimes.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ibtimes.com.au Daily Mail and Mail on Sunday newspapers.